147 related articles for article (PubMed ID: 37666686)
1. Sotorasib after immune checkpoint inhibitor administration induces hepatotoxicity. True, false or just another adverse effect of NSCLC treatment.
Zarogoulidis P; Matthaios D; Oikonomou P; Nikolaou C; Charalampidis C; Sardeli C
Cancer Treat Res Commun; 2023; 37():100757. PubMed ID: 37666686
[TBL] [Abstract][Full Text] [Related]
2. KRAS Inhibitor Resistance in
Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
[TBL] [Abstract][Full Text] [Related]
3. Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRAS
Chour A; Denis J; Mascaux C; Zysman M; Bigay-Game L; Swalduz A; Gounant V; Cortot A; Darrason M; Fallet V; Auclin E; Basse C; Tissot C; Decroisette C; Bombaron P; Giroux-Leprieur E; Odier L; Brosseau S; Creusot Q; Gueçamburu M; Meersseman C; Rochand A; Costantini A; Gaillard CM; Wasielewski E; Girard N; Cadranel J; Lafitte C; Lebossé F; Duruisseaux M
J Thorac Oncol; 2023 Oct; 18(10):1408-1415. PubMed ID: 37217096
[TBL] [Abstract][Full Text] [Related]
4. Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer.
Lee A
Target Oncol; 2022 Nov; 17(6):727-733. PubMed ID: 36315377
[TBL] [Abstract][Full Text] [Related]
5. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L
Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531
[TBL] [Abstract][Full Text] [Related]
6. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
Bungaro M; Novello S; Passiglia F
Curr Treat Options Oncol; 2022 Dec; 23(12):1699-1720. PubMed ID: 36394791
[TBL] [Abstract][Full Text] [Related]
7. Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief report.
Desai A; Rakshit S; Bansal R; Ashara Y; Potter A; Manochakian R; Lou Y; Zhao Y; Ernani V; Savvides P; Schwecke A; Moffett N; Hocum C; Leventakos K; Adjei A; Marks R; Molina J; Mansfield AS; Chen ZM; Dimou A
Cancer Treat Res Commun; 2023; 36():100743. PubMed ID: 37531736
[TBL] [Abstract][Full Text] [Related]
8. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
9. Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal.
Chour A; Basse C; Lebossé F; Bonte PE; Girard N; Duruisseaux M
Lung Cancer; 2024 May; 191():107789. PubMed ID: 38614068
[TBL] [Abstract][Full Text] [Related]
10. [Current status and outlook of medical treatment for
Xu W; Zhuo XL; Liu L; Zhao J; Lin XY; Fu GB
Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):111-116. PubMed ID: 36781231
[TBL] [Abstract][Full Text] [Related]
11. Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC.
Cheema PK; Banerji SO; Blais N; Chu QS; Juergens RA; Leighl NB; Sacher A; Sheffield BS; Snow S; Vincent M; Wheatley-Price PF; Yip S; Melosky BL
Curr Oncol; 2023 Jul; 30(7):6473-6496. PubMed ID: 37504336
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
[TBL] [Abstract][Full Text] [Related]
13. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS
de Langen AJ; Johnson ML; Mazieres J; Dingemans AC; Mountzios G; Pless M; Wolf J; Schuler M; Lena H; Skoulidis F; Yoneshima Y; Kim SW; Linardou H; Novello S; van der Wekken AJ; Chen Y; Peters S; Felip E; Solomon BJ; Ramalingam SS; Dooms C; Lindsay CR; Ferreira CG; Blais N; Obiozor CC; Wang Y; Mehta B; Varrieur T; Ngarmchamnanrith G; Stollenwerk B; Waterhouse D; Paz-Ares L;
Lancet; 2023 Mar; 401(10378):733-746. PubMed ID: 36764316
[TBL] [Abstract][Full Text] [Related]
14. Systemic Therapy for Lung Cancer Brain Metastases.
Pellerino A; Bruno F; Rudà R; Soffietti R
Curr Treat Options Oncol; 2021 Oct; 22(12):110. PubMed ID: 34693454
[TBL] [Abstract][Full Text] [Related]
15. A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.
Kartolo A; Feilotter H; Hopman W; Fung AS; Robinson A
Cancer Treat Res Commun; 2021; 27():100330. PubMed ID: 33581492
[TBL] [Abstract][Full Text] [Related]
16. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.
Zhang B; Zeng J; Zhang H; Zhu S; Wang H; He J; Yang L; Zhou N; Zu L; Xu X; Song Z; Xu S
Front Immunol; 2022; 13():974581. PubMed ID: 36159860
[TBL] [Abstract][Full Text] [Related]
18. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
Hsu PC; Jablons DM; Yang CT; You L
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of immune checkpoint inhibitors in the treatment of non-small cell lung cancer patients with different genes mutation: A meta-analysis.
Zhang R; Zhu J; Liu Y; Xin Y; Wang Y; Niu K; Wei H
Medicine (Baltimore); 2021 Mar; 100(10):e19713. PubMed ID: 33725808
[TBL] [Abstract][Full Text] [Related]
20. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.
Bahnassy AA; Ismail H; Mohanad M; El-Bastawisy A; Yousef HF
J Egypt Natl Canc Inst; 2022 May; 34(1):23. PubMed ID: 35644823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
